Without question, some of BioInformant’s most popular content has been our interviews with key opinion leaders (KOL). Highlighted below are five interviews that have been widely shared across the stem cell industry.
The first interview with Dr. Sadiq has gotten more than 2,200 shares on social media, so you definitely need to check it out. Enjoy!
In breaking news from the Tisch MS Research Center of New York, Dr. Sadiq announced he is pursuing a Phase II clinical trial exploring the use of stem cells in the treatment of MS. The announcement followed positive results from a FDA-approved Phase I stem cell trial in which MS patients received multiple spinal injections of neural progenitors derived from bone marrow mesenchymal stem cells (called MSC-NPs). Compellingly, it was the first time ever that a treatment method has demonstrated reversal of established disability in MS patients.
Joao Andrade, who is leading the exciting development of WideCells Group, gives a glimpse into how the global stem cell services provider aims to revolutionize healthcare. His group has created the world’s first global stem cell healthcare plan, which launched at the World Cord Blood Congress Europe 2016. According to Mr. Andrade, the new medical insurance product could revolutionize stem cell healthcare by making stem cell transplants affordable for families who require treatment for life threatening diseases.
In this interview with the CFO of CryoHoldco, James Alexis Mendez discusses the state of cord blood banking within Latin America. CryoHoldco is a stem cell bank holding company that is the market leader in Latin America and one of the ten largest stem cell banks in the world. With more than 130,000 stored samples, CryoHoldco is more than four times larger than any other stem cell bank in Latin America. CryoHoldco owns the market leaders in both Mexico and Colombia, and plans to expand into other regions of Latin America.
This is an interview with Joseph Krieger, President of Boston Biolife. Boston BioLife is an innovative organization that presents workshops for physicians and scientists to educate them about novel advances in regenerative medicine. Its training programs are characterized by using both didactic and interactive, “hands-on” approaches, which physicians can get ACCME accreditation for attending. Its next event will be “Hands–On Stem Cell Therapies and Biologics for the Clinical Application of Pain Management” in Boston on July 16-17, 2016.
This is an interview with Gregory Block, VP of Business Development for Universal Cells. Universal Cells is a private biotechnology company based in Seattle, Washington, that is revolutionizing the stem cell field by creating stem cells that are universally compatible. Universal Cells’ technology is based on IP exclusively in-licensed from the University of Washington and includes methods for genome editing in human stem cells via homologous recombination with recombinant adeno-associated virus (rAAV) vectors, as well as specific HLA-engineering strategies.
Or, visit our blog to access all recently released interviews and breaking stem cell news.
BioInformant is the first and only market research firm to specialize exclusively in the stem cell industry. BioInformant research has been cited by major news outlets that include the Wall Street Journal, Nature Biotechnology, Medical Ethics, Vogue Magazine, and more. Serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in stem cell industry data.